Standardized Diagnosis and Treatment of Endocrine Hypertension

NCT05149781 | Unknown

• 1 other identifier: 1
• Study Type: observational
• Target: 200
• Locations: 1 country
• Sites: 1

Brief Summary

Cases of endocrine hypertension or primary hypertension who have signed informed consent will be collected. Patients with endocrine hypertension will be divided into surgical treatment group and drug treatment group according to actual treatment situation. A database will be established for all patients. The investigators will comprehensively evaluate the general conditions, past medical history, metabolic and biochemical indicators, psychological status, cardiovascular risk factors. All the patients will be followed up for 12 months at baseline, 6 months and 12 months. Clinical data and specimen will be collected.

Conditions

Endocrine Hypertension

Outcome Measures

Primary Outcomes (1)

• The control rate of blood pressure

  The investigators will compare the proportion of patients with blood pressure below 140/90 mmHg after different treatments.

  12 months

Secondary Outcomes (1)

• Changes of carotid imima-media thickness

  12 months

Study Arms (2)

patients with EH

patients with endocrine hypertension

Procedure: Standardized diagnosis and treatment

patients with PH

patients with primary hypertension

Interventions

Standardized diagnosis and treatment PROCEDURE

Patients with endocrine hypertension undergo surgery or medication depending on the cause after completion of standard diagnostic procedures. Patients with primary hypertension receive medication.

Also known as: antihypertensive drugs

patients with EH

Eligibility Criteria

• Age: 18 Years+
• Sex: all
• Healthy Volunteers: No
• Age Groups: Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with endocrine hypertension or primary hypertension treated at Affiliated Hospital of Nantong University between 2021 and 2024

You may qualify if:

• age≥18 years

You may not qualify if:

• myocardial infarction
• congestive heart failure
• stroke

Sponsors & Collaborators

• Affiliated Hospital of Nantong University: lead

Study Sites (1)

Gu Yunjuan

Nantong, Jiangsu, 226001, China

RECRUITING

Biospecimen

Retention: SAMPLES WITH DNA

blood, urine, adrenal adenoma tissue

MeSH Terms

Interventions

Therapeutics; Antihypertensive Agents

Intervention Hierarchy (Ancestors)

Cardiovascular Agents; Therapeutic Uses; Pharmacologic Actions; Chemical Actions and Uses

Study Officials

• Gu Yunjuan, M.D/Ph.D

  Affiliated Hospital of Nantong University

  PRINCIPAL INVESTIGATOR

Central Study Contacts

Gu Yunjuan, M.D/Ph.D

CONTACT

+8615851207860; desette@ntu.edu.cn

Study Design

• Study Type: observational
• Observational Model: CASE CONTROL
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR

Study Record Dates

• First Submitted: November 25, 2021
• First Posted: December 8, 2021
• Study Start: August 1, 2021
• Primary Completion: January 31, 2024
• Study Completion: July 1, 2024
• Last Updated: September 13, 2023

Record last verified: 2023-08

Locations

CN (1)